KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.

Kerry Conlin, Daniel Jenkin, Philip de Whalley, Lily Yin Weckx, Pedro M Folegatti, Sagida Bibi, Teresa Lambe, Parvinder K Aley, Andrew J Pollard, Merryn Voysey, Sue Ann Costa Clemens, COV003 Study Group

Vaccine 45 126582

PMID39675209
PMCID-
DOI10.1016/j.vaccine.2024.126582
发表日期2024-12-15
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVES: To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes. METHODS: A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group. COVID-19 infections were confirmed by nucleic acid amplification test (NAAT) and classified using the WHO clinical progression scale. Anti-spike antibody responses and serum neutralising activity were measured 28 days after second vaccination in some participants. Exploratory analyses were conducted into factors associated with COVID-19 infection severity and hospitalisation, using logistic regression models adjusted for demographic and clinical factors. RESULTS: 10,416 participants were enrolled; 1790 had NAAT-positive COVID-19 infection; 63 cases required hospitalisation. More severe infection was associated with greater body-mass index (BMI) (odds ratio [OR] = 1.06 [95 %CI: 1.01-1.10], p = 0.01) and diabetes (OR = 3.67 [1.59-8.07], p = 0.003). Hospitalisation risk increased with greater age (OR = 1.06 [1.03-1.08], p < 0.001) and BMI (OR = 1.10 [1.05-1.16], p < 0.001). More severe infection and hospitalisation risks increased >180 days after last vaccination. In the fully vaccinated subgroup (n = 841), only greater age predicted hospitalisation (OR = 1.07 [1.03-1.12], p < 0.001). Serological responses to two vaccine doses diminished with age. CONCLUSIONS: Unvaccinated individuals with high BMI and diabetes risked more severe COVID-19 outcomes. Vaccination mitigated this risk. CLINICAL TRIAL REGISTRATION NUMBER: NCT04536051.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。